Navigation Links
NeurogesX Reports Third Quarter 2009 Results
Date:11/6/2009

elated to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

    NeurogesX, Inc.                     The Ruth Group
    Stephen Ghiglieri                   Sara Pellegrino (investors)
    Chief Financial Officer             (646) 536-7002
    (650) 358-3310                      spellegrino@theruthgroup.com

                                        Jason Rando (media)
                                        (646) 536-7025
                                        jrando@theruthgroup.com
                            NEUROGESX, INC.
           Condensed Consolidated Statements of Operations
            (in thousands, except share and per share data)
                             (unaudited)


                                      Three Months Ended   Nine Months Ended
                                         September 30,        September 30,
                                      ------------------   ------------------
                                       2009        2008      2009       2008
                                       ----        ----      ----       ----
    Collaboration revenue              $119        $--       $119        $--
                                      -----      -----     ------     ------
    Operating expenses:
    Research and development(1)       3,557      3,653      8,664     13,607
    General and administrative(2)     3,269      2,677      8,062      8,027
                                      -----      -----     ------     ------
    Total operating expenses          6,826      6,330     16,726     21,634
                                      -----      -----     ------     ------
    Loss from operations             (6,707)    (6,330)   (16,607)   (21,6
'/>"/>
SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NeurogesX to Present at Two November Conferences
2. NeurogesX to Present at UBS Global Life Sciences Conference
3. NeurogesX to Present at Upcoming Fall Conferences
4. NeurogesX Appoints New Board Director and Audit Committee Chairman
5. NeurogesX Reports Second Quarter 2009 Results
6. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
7. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
8. NeurogesX Added to Russell 3000 Index
9. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
10. NeurogesX to Present at Needham Life Sciences Conference
11. NeurogesX Receives European Commission Approval for Qutenza(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... 30, 2015  Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ... therapeutics that address unmet medical needs in women,s ... will present at the Cantor Fitzgerald Inaugural ... 2015Time: , 4:45 PM EDTLocation: , Le Parker ... , www.juniperpharma.com, under  ,Investor, or  click ...
(Date:6/30/2015)... ... June 30, 2015 , ... The maximum number of ... currently outstanding common shares (including shares of unvested restricted stock). On June 29, 2015, ... sale price of Cryo-Cell’s shares reported on the OTCBB was $2.29 per share. , ...
(Date:6/30/2015)... Dr. Samadi Prostate Cancer Center in New York ... new genetic testing methods for men with an elevated PSA ... Dr. Samadi,s Prostate Cancer Center is ... and optimizing the diagnosis of prostate cancer, both pre-biopsy and ... these revolutionary genetic tests to men with an elevated PSA ...
(Date:6/29/2015)... , June 30, 2015   Pharnext SAS today ... developed for the treatment of Charcot-Marie-Tooth Type 1A (CMT1A), is ... the 2015 Peripheral Nerve Society (PNS) Biennial Meeting at the ... , June 27 - July 2, 2015. At ... Wed July 1, 5p.m. to 7p.m. EDT: ...
Breaking Biology Technology:Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 4New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 5Pharnext's PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting 2
... Key Secondary Endpoints,NEW YORK, March 10 Intra-Cellular Therapies, ... Phase II trial in patients with Sleep Maintenance Insomnia ... increased slow wave sleep and decreased the duration of ... meeting the prespecified primary and key secondary endpoints of ...
... March 9 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ... positive clinical study results for its Bio-Seal(TM) Lung ... Interventional Radiologists Annual Scientific Meeting in San Diego, ... of Bio-Seal in patients undergoing lung biopsy procedures ...
... 9 Former Presidential candidate Gary Bauer on Monday called ... embryonic stem cell research "evidence that ideology is the goal ... a tragedy, as lives will be lost and not saved ... Values made the following statement: "It,s tragic that Barack Obama ...
Cached Biology Technology:Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 2Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 3Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 4Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 5Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 6Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 7Angiotech announces positive results from Bio-Seal(TM) clinical study 2Angiotech announces positive results from Bio-Seal(TM) clinical study 3Angiotech announces positive results from Bio-Seal(TM) clinical study 4Angiotech announces positive results from Bio-Seal(TM) clinical study 5
(Date:6/26/2015)... ATL Technology, LLC, a top provider of electromechanical ... use solutions, headquartered in Springville, Utah , ... California corporation with locations in Santa ... Rica ). This acquisition will incorporate MedConx,s ... ATL Technology,s existing facility in Costa Rica ...
(Date:6/24/2015)... 24, 2015 This report provides market analysis ... six years. It contains an analysis of the drivers, ... their impact from the short, medium, and long term ... industry, market, and technology trends that currently, prevail in ... concerned authorities to efficiently manage the increasing marine traffic ...
(Date:6/23/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/vq2k2f/bodyworn ... "Body-Worn Temperature Sensors Market - Global Industry Analysis, ... 2020" report to their offering. ... body-worn temperature sensors market. The global body-worn temperature ... of types, care setting, patient demographic, applications and ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2
... A team from the National Institute of Standards ... Guard on a coordinated effort to train emergency first ... securing reliable samples of suspected biothreats. The project, dubbed ... first responders at the state, local and federal levels ...
... in the journal Annals of Botany , Professor Douglas ... in the ground could harvest more carbon from the air, ... levels. In principle, any crops could be treated in ... for the environment. Although the amount of carbon presently ...
... Nobel Prize for nerve growth factor was awarded more than ... use growth factor clinically. University of Pittsburgh Professor Yadong ... factor to regrow blood vessels. His research, which could be ... death in the Western world, is published this week in ...
Cached Biology News:Operation Vigilant Sample: First responder training for suspicious powders 2Crop breeding could 'slash CO2 levels' 2Regrowing blood vessels with a potent molecule 2Regrowing blood vessels with a potent molecule 3Regrowing blood vessels with a potent molecule 4
...
... feature a dual strength adhesive system which facilitates ... The adhesives on either side of the frame ... to the glass has an easy release adhesive ... forms a stronger bond. This means that when ...
... Cultures (ECACC) has been offering training courses ... institutes for over seven years. We offer ... candidates to cell culture and a Level ... areas such as planning and management of ...
... cover slips for in situ hybridization,in ... on glass slides., Constant probe ... not adsorb probes. , Ready-to-use-Hybri-slips do ... , Avoid RNA degradation-Hybri-slips are supplied ...
Biology Products: